AVTX
NASDAQ · Biotechnology
Avalo Therapeutics Inc
$7.76
+0.06 (+0.78%)
Open$7.73
Previous Close$7.70
Day High$7.94
Day Low$7.45
52W High$24.27
52W Low$6.53
Volume—
Avg Volume1.99M
Market Cap453.04M
P/E Ratio—
EPS$-4.75
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+324.1% upside
Current
$7.76
$7.76
Target
$32.91
$32.91
$27.78
$32.91 avg
$47.11
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 258.9K | 1.74M | 36.29M |
| Net Income | -343,489,587 | -2,083,157,872 | 8.09M |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% |
| EBITDA | -318,572,177 | -2,039,377,143 | 9.50M |
| Free Cash Flow | — | — | 4.67M |
| Rev Growth | -85.2% | -85.2% | +16.8% |
| Debt/Equity | 0.03 | 0.03 | 0.47 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |